Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics

References

• Chehade JM Mooradian AD A rational approach to drug therapy of type 2 diabetes mellitus Drugs 2000 60 1 95 113 10929931
   PubMed Web of Science ®Google Scholar
• Carpino PA Goodwin B Diabetes area participation analysis: a review of companies and targets described in the 2008–2010 patent literature Expert Opin Ther 2010 20 12 1627 1651
   Web of Science ®Google Scholar
• Wild S Roglic G Green A Sicree R King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27 5 1047 1053 15111519
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Pathogenesis of type 2 diabetes mellitus Med Clin North Am 2004 88 4 787 835 ix 15308380
   PubMed Web of Science ®Google Scholar
• Berger J Moller DE The mechanisms of action of PPARs Annu Rev Med 2002 53 409 435 11818483
   PubMed Web of Science ®Google Scholar
• Berger JP Akiyama TE Meinke PT PPARs: therapeutic targets for metabolic disease Trends Pharmacol Sci 2005 26 5 244 251 15860371
   PubMed Web of Science ®Google Scholar
• Markt P Schuster D Kirchmair J Laggner C Langer T Pharmacophore modeling and parallel screening for PPAR ligands J Comput Aided Mol Des 2007 21 10–11 575 590 17960326
   PubMed Web of Science ®Google Scholar
• van Raalte DH Li M Pritchard PH Wasan KM Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future Pharm Res 2004 21 9 1531 1538 15497675
   PubMed Web of Science ®Google Scholar
• Issemann I Prince RA Tugwood JD Green S The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs J Mol Endocrinol 1993 11 1 37 47 8240670
   PubMed Web of Science ®Google Scholar
• Evans RM Barish GD Wang YX PPARs and the complex journey to obesity Nat Med 2004 10 4 355 361 15057233
   PubMed Web of Science ®Google Scholar
• Semple RK Chatterjee VK O’Rahilly S PPAR gamma and human metabolic disease J Clin Invest 2006 116 3 581 589 16511590
   PubMed Web of Science ®Google Scholar
• Lehmann JM Moore LB Smith-Oliver TA Wilkison WO Wilson TM Klieweer SA An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Biol Chem 1995 270 22 12953 12956 7768881
   PubMed Web of Science ®Google Scholar
• Rosen ED Spiegelman BM PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth J Biol Chem 2001 276 41 37731 37734 11459852
   PubMed Web of Science ®Google Scholar
• Henke BR Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes J Med Chem 2004 47 17 4118 4127 15293980
   PubMed Web of Science ®Google Scholar
• Mochizuki K Suruga K Yagi E Takase S Goda T The expression of PPAR-associated genes is modulated through postnatal development of PPAR subtypes in the small intestine Biochim Biophys Acta 2001 1531 1–2 68 76 11278173
   PubMed Web of Science ®Google Scholar
• Jones RM New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches London, UK RSC Publishing 2012
   Google Scholar
• Chou KC Structural bioinformatics and its impact to biomedical science Curr Med Chem 2004 11 16 2105 2134 15279552
   PubMed Web of Science ®Google Scholar
• Chou KC Wei DQ Zhong WZ Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS Biochem Biophys Res Commun 2003 308 1 148 151 12890493
   PubMed Web of Science ®Google Scholar
• Sirois S Wei DQ Du QS Chou KC Virtual Screening for SARS-CoV protease based on KZ7088 pharmacophore points J Chem Inf Comput Sci 2004 44 3 1111 1122 15154780
   PubMedGoogle Scholar
• Dea-Ayuela MA Pérez-Castillo Y Meneses-Marcel A HP-Lattice QSAR for dynein proteins: experimental proteomics (2D-electrophoresis, mass spectrometry) and theoretic study of a Leishmania infantum sequence Bioorg Med Chem 2008 16 16 7770 7776 18662882
   PubMed Web of Science ®Google Scholar
• Prado-Prado FJ González-Díaz H de la Vega OM Ubeira FM Chou KC Unified QSAR approach to antimicrobials. Part 3: First multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds Bioorg Med Chem 2008 16 11 5871 5880 18485714
   PubMed Web of Science ®Google Scholar
• Prado-Prado FJ Martinez de la Vega O Uriarte E Ubeira FM Chou KC González-Díaz H Unified QSAR approach to antimicrobials. 4. Multitarget QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks Bioorg Med Chem 2009 17 2 569 575 19112024
   PubMed Web of Science ®Google Scholar
• Du QS Huang RB Wei YT Pang ZW Du LQ Chou KC Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design J Comput Chem 2009 30 2 295 304 18613071
   PubMed Web of Science ®Google Scholar
• Hou X Du J Fang H Li M 3D-QSAR study on a series of Bcl-2 protein inhibitors using comparative molecular field analysis Protein Pept Lett 2011 18 5 440 449 21171944
   PubMed Web of Science ®Google Scholar
• Lin WZ Xiao X Chou KC GPCR-GIA: a web-server for identifying G-protein coupled receptors and their families with grey incidence analysis Protein Eng Des Sel 2009 22 11 699 705 19776029
   PubMed Web of Science ®Google Scholar
• Xiao X Wang P Chou KC GPCR-2L: predicting G protein-coupled receptors and their types by hybridizing two different modes of pseudo amino acid compositions Mol Biosyst 2011 7 3 911 919 21180772
   PubMedGoogle Scholar
• Chou KC Wu ZC Xiao X iLoc-Euk: a multi-label classifier for predicting the subcellular localization of singleplex and multiplex eukaryotic proteins PLoS One 2011 6 3 e18258 21483473
   PubMed Web of Science ®Google Scholar
• Chou KC Wu ZC Xiao X iLoc-Hum: using accumulation-label scale to predict subcellular locations of human proteins with both single and multiple sites Mol Biosyst 2012 8 2 629 641 22134333
   PubMedGoogle Scholar
• Wang P Xiao X Chou KC NR-2L: a two-level predictor for identifying nuclear receptor subfamilies based on sequence-derived features PLoS One 2011 6 8 e23505 21858146
   PubMed Web of Science ®Google Scholar
• Chou KC Shen HB ProtIdent: a web server for identifying proteases and their types by fusing functional domain and sequential evolution information Biochem Biophys Res Commun 2008 376 2 321 325 18774775
   PubMed Web of Science ®Google Scholar
• Shen HB Chou KC HIVcleave: a web-server for predicting human immunodeficiency virus protease cleavage sites in proteins Anal Biochem 2008 375 2 388 390 18249180
   PubMed Web of Science ®Google Scholar
• Chou KC Prediction of human immunodeficiency virus protease cleavage sites in proteins Anal Biochem 1996 233 1 1 14 8789141
   PubMed Web of Science ®Google Scholar
• Richards WG Virtual screening using grid computing: the screensaver project Nat Rev Drug Discov 2002 1 7 551 555 12120261
   PubMed Web of Science ®Google Scholar
• Roche O Schneider P Zuegge J Development of a virtual screening method for identification of “frequent hitters” in compound libraries J Med Chem 2002 45 1 137 142 11754585
   PubMed Web of Science ®Google Scholar
• Senger S Using Tversky similarity searches for core hopping: finding the needles in the haystack J Chem Inf Model 2009 49 6 1514 1524 19453147
   PubMed Web of Science ®Google Scholar
• Henke BR Consler TG Go N A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta J Med Chem 2002 45 25 5492 5505 12459017
   PubMed Web of Science ®Google Scholar
• Li XB Wang SQ Xu WR Wang RL Chou KC Novel inhibitor design for hemagglutinin against H1N1 influenza virus by core hopping method PLoS One 2011 6 11 e28111 22140516
   PubMed Web of Science ®Google Scholar
• Ma Y Wang SQ Xu WR Wang RL Chou KC Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach PLoS One 2012 7 6 e38546 22685582
   PubMed Web of Science ®Google Scholar
• Eldridge MD Murray CW Auton TR Paolini GV Mee RP Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J Comput Aided Mol Des 1997 11 5 425 445 9385547
   PubMed Web of Science ®Google Scholar
• Halgren TA Murphy RB Friesner RA Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J Med Chem 2004 47 7 1750 1759 15027866
   PubMed Web of Science ®Google Scholar
• Jorgensen WL Duffy EM Prediction of drug solubility from structure Adv Drug Deliv Rev 2002 54 3 355 366 11922952
   PubMed Web of Science ®Google Scholar
• Tian S Li Y Wang J Zhang J Hou T ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints Mol Pharm 2011 8 3 841 851 21548635
   PubMed Web of Science ®Google Scholar
• Xu HE Lambert MH Montana VG Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors Proc Natl Acad Sci USA 2001 98 24 13919 13924 11698662
   PubMed Web of Science ®Google Scholar
• Berman HM Battistuz T Bhat TN The Protein Data Bank Acta Crystallogr D Biol Crystallogr 2002 58 Pt 61 899 907 12037327
   PubMedGoogle Scholar
• Husslein T Moore PB Zhong Q Newns DM Pattnaik PC Klein ML Molecular dynamics simulation of a hydrated diphytanol phosphatidylcholine lipid bilayer containing an alpha-helical bundle of four transmembrane domains of the influenza A virus M2 protein Faraday Discuss 1998 111 201 208 discussion 225 246 10822610
   PubMed Web of Science ®Google Scholar
• Kochendoerfer GG Salom D Lear JD Wilk-Orescan R Kent SB DeGrado WF Total chemical synthesis of the integral membrane protein influenza A virus M2: role of its C-terminal domain in tetramer assembly Biochemistry 1999 38 37 11905 11913 10508393
   PubMed Web of Science ®Google Scholar
• Gandhi CS Shuck K Lear JD Cu(II) inhibition of the proton translocation machinery of the influenza A virus M2 protein J Biol Chem 1999 274 9 5474 5482 10026160
   PubMed Web of Science ®Google Scholar
• Feige JN Gelman L Tudor C Engelborghs Y Wahli W Desvergne B Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand J Biol Chem 2005 280 18 17880 17890 15731109
   PubMed Web of Science ®Google Scholar
• Irwin JJ Schoichet BK ZINC – a free database of commercially available compounds for virtual screening J Chem Inf Model 2005 45 1 177 182 15667143
   PubMed Web of Science ®Google Scholar
• Banks JL Beard HS Cao Y Integrated Modeling Program, Applied Chemical Theory (IMPACT) J Comput Chem 2005 26 16 1752 1780 16211539
   PubMed Web of Science ®Google Scholar
• Liao QH Gao QZ Wei J Chou KC Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR) Med Chem 2011 7 1 24 31 21235516
   PubMed Web of Science ®Google Scholar
• Cai L Wang Y Wang JF Chou KC Identification of proteins interacting with human SP110 during the process of viral infections Med Chem 2011 7 2 121 126 21222611
   PubMed Web of Science ®Google Scholar
• Liu XY Wang RL Xu WR Tang LD Wang SQ Chou KC Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar Protein Pept Lett 2011 18 10 1021 1027 21592078
   PubMed Web of Science ®Google Scholar
• Chou KC The biological functions of low-frequency vibrations (phonons). 4. Resonance effects and allosteric transition Biophys Chem 1984 20 1–2 61 71 6487745
   PubMed Web of Science ®Google Scholar
• Wang JF Gong K Wei DQ Li YX Chou KC Molecular dynamics studies on the interactions of PTP1B with inhibitors: from the first phosphate-binding site to the second one Protein Eng Des Sel 2009 22 6 349 355 19380334
   PubMed Web of Science ®Google Scholar
• Chou KC Low-frequency resonance and cooperativity of hemoglobin Trends Biochem Sci 1989 14 6 212 213 2763333
   PubMed Web of Science ®Google Scholar
• Chou KC The biological functions of low-frequency vibrations (phonons). III. Helical structures and microenvironment Biophys J 1984 45 5 881 889 6428481
   PubMed Web of Science ®Google Scholar
• Lian P Wei DQ Wang JF Chou KC An allosteric mechanism inferred from molecular dynamics simulations on phospholamban pentamer in lipid membranes PLoS One 2011 6 4 e18587 21525996
   PubMed Web of Science ®Google Scholar
• Chou KC The biological functions of low-frequency vibrations (phonons): VI. A possible dynamic mechanism of allosteric transition in antibody molecules Biopolymers 1987 26 2 285 295 3828475
   PubMed Web of Science ®Google Scholar
• Chou KC Mao B Collective motion in DNA and its role in drug intercalation Biopolymers 1988 27 11 1795 1815 3233332
   PubMed Web of Science ®Google Scholar
• Chou KC Zhang CT Maggiora GM Solitary wave dynamics as a mechanism for explaining the internal motion during microtubule growth Biopolymers 1994 34 1 143 153 8110966
   PubMed Web of Science ®Google Scholar
• Chou KC Low-frequency collective motion in biomacromolecules and its biological functions Biophys Chem 1988 30 1 3 48 3046672
   PubMed Web of Science ®Google Scholar
• Schnell JR Chou JJ Structure and mechanism of the M2 proton channel of influenza A virus Nature 2008 451 7178 591 595 18235503
   PubMed Web of Science ®Google Scholar
• Huang RB Du QS Wang CH Chou KC An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus Biochem Biophys Res Commun 2008 377 4 1243 1247 18996090
   PubMed Web of Science ®Google Scholar
• Oostenbrink C Soares TA van der Vegt NF van Gunsteren WF Validation of the 53A6 GROMOS force field Eur Biophys J 2005 34 4 273 284 15803330
   PubMed Web of Science ®Google Scholar
• Schüttelkopf AW van Aalten DM PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr D Biol Crystallogr 2004 60 Pt 8 1355 1363 15272157
   PubMedGoogle Scholar
• Bhaya A Kaszkurewicz E Steepest descent with momentum for quadratic functions is a version of the conjugate gradient method Neural Netw 2004 17 1 65 71 14690708
   PubMed Web of Science ®Google Scholar
• Deift P Venakides S Zhou X An extension of the steepest descent method for Riemann-Hilbert problems: the small dispersion limit of the Korteweg-de Vries (KdV) equation Proc Natl Acad Sci USA 1998 95 2 450 454 11038618
   PubMed Web of Science ®Google Scholar
• Cerutti DS Duke RE Darden TA Lybrand TP Staggered Mesh Ewald: An extension of the Smooth Particle-Mesh Ewald method adding great versatility J Chem Theory Comput 2009 5 9 2322 20174456
   PubMed Web of Science ®Google Scholar
• Hess B Bekker H Berendsen HJC Fraaije JGEM LINCS: a linear constraint solver for molecular simulations J Comput Chem 1998 18 12 1463 1472
   Web of Science ®Google Scholar
• Liu XY Wang RL Xu WR Tang LD Wang SQ Chou KC Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar Protein Pept Lett 2011 18 10 1021 1027 21592078
   PubMed Web of Science ®Google Scholar
• Liu Y Hong L Yu LS The role of ADME evaluation in translation research of innovative drug Yao Xue Xue Bao 2011 46 1 19 29 Chinese 21465804
   PubMedGoogle Scholar
• Jorgensen WL Duffy EM Prediction of drug solubility from Monte Carlo simulations Bioorg Med Chem Lett 2000 10 11 1155 1158 10866370
   PubMed Web of Science ®Google Scholar
• Singh KHD Kirubakaran P Nagarajan S Homology modeling, molecular dynamics, e-pharmacophore mapping and docking study of Chikungunya virus nsP2 protease J Mol Model 2012 18 1 39 51 21445710
   PubMed Web of Science ®Google Scholar
• Pickavance LC Brand CL Wassermann K Wilding JP The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats Br J Pharmacol 2005 144 3 308 316 15655531
   PubMed Web of Science ®Google Scholar
• Waites CR Dominick MA Sanderson TP Schilling BE Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist Toxicol Sci 2007 100 1 248 258 17675651
   PubMed Web of Science ®Google Scholar
• Heppner TJ Bonev AD Eckman DM Gomez MF Petkov GV Nelson MT Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries Pharmacology 2005 73 1 15 22 15452359
   PubMed Web of Science ®Google Scholar
• Ding L Liang XG Lou YJ Time-dependence of cardiomyocyte differentiation disturbed by peroxisome proliferator-activated receptor alpha inhibitor GW6471 in murine embryonic stem cells in vitro Acta Pharmacol Sin 2007 28 5 634 642 17439719
   PubMed Web of Science ®Google Scholar
• Sauerberg P Pettersson I Jeppesen L Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity J Med Chem 2002 45 4 789 804 11831892
   PubMed Web of Science ®Google Scholar
• Scarsi M Podvinec M Roth A Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach Mol Pharmacol 2007 71 2 398 406 17082235
   PubMed Web of Science ®Google Scholar
• Pavankuamr VV Vinu CA Mullangi R Srinivas NR Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator Eur J Drug Metab Pharmacokinet 2007 32 1 29 37 17479541
   PubMed Web of Science ®Google Scholar
• Skrumsager BK Nielsen KK Müller M Pabst G Drake PG Edsberg B Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes J Clin Pharmacol 2003 43 11 1244 1256 14551179
   PubMed Web of Science ®Google Scholar
• Chakrabarti R Vikramadithyan RK Misra P Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models Br J Pharmacol 2003 140 3 527 537 12970088
   PubMed Web of Science ®Google Scholar
• Ebdrup S Pettersson I Rasmussen HB Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar J Med Chem 2003 46 8 1306 1317 12672231
   PubMed Web of Science ®Google Scholar
• Chou KC Watenpaugh KD Heinrikson RL A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator Biochem Biophys Res Commun 1999 259 2 420 428 10362524
   PubMed Web of Science ®Google Scholar
• Chou KC Molecular therapeutic target for type-2 diabetes J Proteome Res 2004 3 6 1284 1288 15595739
   PubMed Web of Science ®Google Scholar
• Pielak RM Schnell JR Chou JJ Mechanism of drug inhibition and drug resistance of influenza A M2 channel Proc Natl Acad Sci USA 2009 106 18 7379 7384 19383794
   PubMed Web of Science ®Google Scholar
• Wang JF Chou KC Insights from modeling the 3D structure of New Delhi metallo-β-lactamase and its binding interactions with antibiotic drugs PLoS One 2011 6 4 e18414 21494599
   PubMed Web of Science ®Google Scholar
• Housaindokht MR Bozorgmehr MR Bahrololoom M Analysis of ligand binding to proteins using molecular dynamics simulations J Theor Biol 2008 254 2 294 300 18599089
   PubMed Web of Science ®Google Scholar
• Wang JF Chou KC Insights into the mutation-induced HHH syndrome from modeling human mitochondrial ornithine transporter-1 PLoS One 2012 7 1 e31048 22292090
   PubMed Web of Science ®Google Scholar
• Chou KC Insights from modeling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor Biochem Biophys Res Commun 2004 319 2 433 438 15178425
   PubMed Web of Science ®Google Scholar
• Chou KC Watenpaugh KD Heinrikson RL A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator Biochem Biophys Res Commun 1999 259 2 420 428 10362524
   PubMed Web of Science ®Google Scholar